Recurrent Glioblastoma
Conditions
Brief summary
This randomized phase II trial studies how well cediranib maleate and olaparib work compared to bevacizumab in treating patients with glioblastoma that has come back (recurrent). Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Detailed description
PRIMARY OBJECTIVES: I. To compare the antitumor activity of cediranib maleate (cediranib)/olaparib versus reference bevacizumab monotherapy, as measured by progression-free survival at 6 months (PF6), in patients with recurrent glioblastoma (GBM). SECONDARY OBJECTIVES: I. To compare overall survival (OS), progression free survival (PFS) and objective response (ORR) in patients with recurrent GBM treated with cediranib/olaparib versus bevacizumab. II. To assess the safety of the combination of olaparib and cediranib in patients with recurrent GBM. III. To evaluate the association of blood based biomarkers involved with angiogenesis using the Biomarker Review Committee-approved Plasma Angiome Panel (bFGF, Ang-1, Ang-2, Tie-2, SDF1-alpha, Collagen IV, PlGF, sVEGFR1, sVEGFR2, VEGF, Il-1beta, Il-6, Il-8, TNF-alpha, CAIX) with the clinical activity of cediranib/olaparib. IV. To evaluate the association of tissue biomarkers involved with deoxyribonucleic acid (DNA) repair using the Biomarker Review Committee-approved BROCA panel with the clinical activity of cediranib/olaparib. V. To identify genomic alteration by whole exome sequencing in GBM tumor specimens that correlate with the clinical activity of cediranib/olaparib. VI. To evaluate the association of magnetic resonance imaging (MRI) imaging parameters (tumor perfusion and oxygenation, brain tumor cellularity) with the biological response of cediranib/olaparib. VII. To contribute genetic analysis data from de-identified biospecimens to Genomic Data Commons (GDC), a well annotated cancer molecular and clinical data repository, for current and future research; specimens will be annotated with key clinical data, including presentation, diagnosis, staging, summary treatment, and if possible, outcome. VIII. To bank formalin-fixed, paraffin-embedded (FFPE) tissue, blood (for cell-free DNA analysis), and nucleic acids obtained from patients at the Experimental Therapeutics Clinical Trials Network (ETCTN) Biorepository at Nationwide Children's Hospital. OUTLINE: Patients are randomized to 1 of 2 arms. ARM A: Patients receive olaparib orally (PO) twice daily (BID) and cediranib maleate PO once daily (QD) on days 1-28. ARM B: Patients receive bevacizumab intravenously (IV) over 30-90 minutes every 2 weeks. In both arms, cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days and then periodically for 3 years.
Interventions
BIOLOGICALBevacizumab
Given IV
DRUGCediranib
Given PO
DRUGCediranib Maleate
Given PO
DRUGOlaparib
Given PO
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Unequivocal evidence of progressive disease on contrast-enhanced brain computed tomography (CT) or MRI as defined by Response Assessment in Neuro-Oncology (RANO) criteria, or have documented recurrent glioblastoma on diagnostic biopsy * Previous therapy with at least radiotherapy and temozolomide * Must be 12 weeks from radiotherapy; if patients are within 12 weeks of radiotherapy, then the progressive lesion must be outside of the high-dose radiation target volume or have unequivocal evidence of progressive tumor on a biopsy specimen * Only first and second recurrences of GBM are eligible * From the projected start of scheduled study treatment, the following time periods must have elapsed: 5 half-lives from investigational agents, 4 weeks from cytotoxic therapy (except 23 days for temozolomide and 6 weeks from nitrosoureas), 6 weeks from antibodies, or 4 weeks (or 5 half-lives, whichever is shorter) from other systemic anti-tumor therapies; treatment on study may start one day after discontinuation of the optune device * All adverse events grade \> 1 related to prior therapies (chemotherapy, radiotherapy, and/or surgery) must be resolved, except for alopecia * Willingness to release archival tissue sample for research purposes, if available * Karnofsky performance status \>= 60 * Life expectancy of at least 3 months * Leukocytes \>= 3,000/mcL * Absolute neutrophil count \>= 1,500/mcL * Platelets \>= 100,000/mcL * Hemoglobin \>= 10.0 g/dL and no blood transfusions in the 28 days prior to entry/randomization * Total bilirubin =\< 1.5 x institutional upper limit of normal (ULN) * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 x institutional upper limit of normal * Creatinine should not exceed the institutional upper limit of normal OR creatinine clearance \>= 60 mL/min/1.73 m\^2 * Urine protein: creatinine (UPC) ratio \< 1 or urine dipstick for proteinuria =\< 2+ (note: if the UPC ratio is \>= 1.0 then a 24-hour urine collection should be performed and this must demonstrate =\< 1 g of protein in 24 hours) * CT or MRI within 14 days prior to start of study drug * Corticosteroid dose must be stable or decreasing for at least 5 days prior to the baseline MRI scan * The effects of olaparib and cediranib on the developing human fetus are unknown; female subjects must either be of non-reproductive potential, not breast-feeding or must have a negative urine or serum pregnancy test within 28 days of study treatment, confirmed prior to treatment on day 1; women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of olaparib + cediranib administration * Ability to understand and the willingness to sign a written informed consent document
Exclusion criteria
* Participants should not have received any other investigational agents nor have participated in an investigational trial within the past 4 weeks * Participants may not have had prior use of PARP inhibitors; patients may not have received prior treatment affecting the VEGF pathway including but not limited to thalidomide, bevacizumab, sunitinib, or sorafenib * Patients who are receiving any other investigational agents * History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib, cediranib or bevacizumab * Participants may not have any evidence of ongoing inadequately controlled hypertension (defined as a systolic blood pressure \[BP\] of \> 140 mmHg or a diastolic BP of \> 90 mmHg); patients with hypertension may not be on more than three antihypertensive medications for management of their blood pressure (medications that combine two anti-hypertensives into one are considered as two medications); it is strongly recommended that patients who require three antihypertensive medications for baseline management of pre-existing hypertension be actively followed by a cardiologist or blood pressure specialist for management of BP while on protocol * Participants may not have had any prior history of hypertensive crisis or hypertensive encephalopathy * Participants may not have had history of abdominal fistula or gastrointestinal perforation within the past 6 months * Participants may not have had a history of intra-abdominal abscess within the past 6 months * Patients may not have a known or confirmed history of pneumonitis * Participants may not have current signs and/or symptoms of bowel obstruction or signs and/or symptoms of bowel obstruction within 3 months prior to starting study drugs * Participants may not have a dependency on IV hydration or total parenteral nutrition (TPN) * Patients with myelodysplastic syndrome/acute myeloid leukemia * Participants with any concomitant or prior invasive malignancies are ineligible with the following exceptions: * Treated limited-stage basal cell or squamous cell carcinoma of the skin * Carcinoma in situ of the breast or cervix * Prior cancer treated with curative intent with no evidence of recurrent disease 3 years following diagnosis and judged by the investigator to be at low risk of recurrence * Participants with any of the following: * History of myocardial infarction within six months * Unstable angina * History of cerebrovascular accident (CVA) within 6 months * New York Heart Association grade II or greater congestive heart failure * Significant vascular disease (e.g. aortic aneurysm, history of aortic dissection) * Clinically significant peripheral vascular disease * If cardiac function assessment is clinically indicated or performed: participants will be ineligible if left ventricular ejection fraction (LVEF) is less than normal per institutional guidelines, or \< 55%, if the threshold for normal is not otherwise specified by institutional guidelines * Participants may not have corrected QT (QTc) \> 470 msec or family history of long QT syndrome * Participants may not have a major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting cediranib; anticipation of need for major surgical procedures during the course of the study also excludes patients from the trial * Participants should not have any uncontrolled intercurrent illness including, but limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Participants receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 or moderate inhibitors of CYP3A4 are ineligible; the study team should check a frequently-updated medical reference for a list of drugs to avoid or minimize use of; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product; dihydropyridine calcium-channel blockers are permitted for management of hypertension; patient drug information handout and wallet card should be provided to patients * Pregnant women are excluded from this study because cediranib and olaparib agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with cediranib and olaparib breastfeeding should be discontinued if the mother is treated with cediranib and olaparib; these potential risks may also apply to other agents used in this study * Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with cediranib and olaparib; in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated * Current use of a prohibited medication; the following medications or non-drug therapies are prohibited: * Other anti-cancer therapy while on study treatment * Concurrent treatment with bisphosphonates is permitted; however, treatment must be initiated prior to the first dose of study therapy; prophylactic use of bisphosphonates in patients without bone disease is not permitted, except for the treatment of osteoporosis * Because the composition, pharmacokinetics (PK), and metabolism of many herbal supplements are unknown; the concurrent use of all herbal supplements is prohibited during the study (including, but not limited to, cannabis, S. John's wort, kava, ephedra \[ma huang\], gingko biloba, dehydroepiandrosterone \[DHEA\], yohimbe, saw palmetto or ginseng) * Raloxifene is allowed for patients taking it for bone health * Participants should not have evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Progression-Free Survival at 6 Months | 6 months | Progression-Free Survival (PFS) is defined as the time from randomization to progressive disease (PD) per Response Assessment in Neuro-Oncology (RANO) criteria, or death due to any cause, whichever occurs first. Participants alive without PD are censored at date of last disease evaluation. PD criteria: (A) 25% increase in sum of the products of perpendicular diameters of enhancing lesions (over best response or baseline if no decrease) on stable or increasing doses of steroids and/or one or more of the following: (B) Significant increase in T2/FLAIR non-enhancing lesion on stable or increasing doses of steroids compared to baseline scan or best response following initiation of therapy, not due to co-morbid events (C) Any new lesions (D) Clear clinical deterioration not attributable to other causes apart from the tumor, per discretion of the treating physician (E) Failure to return for evaluation due to death or deteriorating condition. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival | Up to 3 years | Progression free survival is defined as the time from randomization until progressive disease or death from any cause. |
| Overall Survival (OS) | up to 3 years | Overall Survival (OS) is defined as the time from randomization to death due to any cause, or censored at date last known alive. |
| Incidence of Adverse Events (AE) | Up to 3 years | The grade of adverse events be assessed by National Cancer Institute Common Terminology Criteria for Adverse Events 5.0. The incidence of an adverse event at a particular grade is the number of patients who experienced that adverse event/grade. |
| Levels of Circulating Cytokines Involved With Angiogenesis | Up to 3 years | Descriptive statistics will be provided for all continuous biomarkers outcomes. Contingency tables will be provided for categorical data. All comparisons between study arms will be adjusted for multiplicity and in particular false discovery rate (FDR) (Hochberg and Binaymini) will be used for genome data. Binary endpoints will be reported using 95% binomial confidence intervals. |
| Levels of Serial Circulating Biomarkers Involved With Deoxyribonucleic Acid (DNA) Repair | Up to 3 years | Descriptive statistics will be provided for all continuous biomarkers outcomes. Contingency tables will be provided for categorical data. All comparisons between study arms will be adjusted for multiplicity and in particular FDR (Hochberg and Binaymini) will be used for genome data. Binary endpoints will be reported using 95% binomial confidence intervals. |
| Tumor Genomic Alteration | Up to 3 years | Will be assessed by whole exome sequencing. Descriptive statistics will be provided for all continuous biomarkers outcomes. Contingency tables will be provided for categorical data. All comparisons between study arms will be adjusted for multiplicity and in particular FDR (Hochberg and Binaymini) will be used for genome data. Binary endpoints will be reported using 95% binomial confidence intervals. |
| Imaging Correlates (Vascular Permeability, Tumor Perfusion and Oxygenation, Brain Tumor Cellularity) | Up to 3 years | Descriptive statistics will be provided for all continuous biomarkers outcomes. Contingency tables will be provided for categorical data. All comparisons between study arms will be adjusted for multiplicity and in particular FDR (Hochberg and Binaymini) will be used for genome data. Binary endpoints will be reported using 95% binomial confidence intervals. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORIsabel Arrillaga-Romany
Dana-Farber - Harvard Cancer Center LAO
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Arm A (Olaparib, Cediranib Maleate) Patients receive olaparib PO BID and cediranib maleate PO once QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cediranib: Given PO
Cediranib Maleate: Given PO
Olaparib: Given PO | 35 |
| Arm B (Bevacizumab) Patients receive bevacizumab IV over 30-90 minutes every 2 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Bevacizumab: Given IV | 35 |
| Total | 70 |
Baseline characteristics
| Characteristic | Arm A (Olaparib, Cediranib Maleate) | Arm B (Bevacizumab) | Total |
|---|---|---|---|
| Age, Continuous | 60.0 years | 61.0 years | 60.5 years |
| IDH mutation No | 26 Participants | 29 Participants | 55 Participants |
| IDH mutation Unknown | 1 Participants | 1 Participants | 2 Participants |
| IDH mutation Yes | 8 Participants | 5 Participants | 13 Participants |
| Karnofsky performance status Score = 100 | 3 Participants | 6 Participants | 9 Participants |
| Karnofsky performance status Score = 60 | 0 Participants | 2 Participants | 2 Participants |
| Karnofsky performance status Score = 70 | 7 Participants | 6 Participants | 13 Participants |
| Karnofsky performance status Score = 80 | 12 Participants | 7 Participants | 19 Participants |
| Karnofsky performance status Score = 90 | 13 Participants | 14 Participants | 27 Participants |
| MGMT promoter methylation Indeterminate | 2 Participants | 1 Participants | 3 Participants |
| MGMT promoter methylation Methylated | 11 Participants | 13 Participants | 24 Participants |
| MGMT promoter methylation Unknown | 7 Participants | 9 Participants | 16 Participants |
| MGMT promoter methylation Unmethylated | 15 Participants | 12 Participants | 27 Participants |
| Number of Disease Recurrence 1 recurrence | 22 Participants | 27 Participants | 49 Participants |
| Number of Disease Recurrence 2 recurrences | 13 Participants | 8 Participants | 21 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants | 1 Participants | 3 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 3 Participants | 1 Participants | 4 Participants |
| Race (NIH/OMB) White | 29 Participants | 33 Participants | 62 Participants |
| Sex: Female, Male Female | 14 Participants | 13 Participants | 27 Participants |
| Sex: Female, Male Male | 21 Participants | 22 Participants | 43 Participants |
| Surgery Biopsy | 2 Participants | 8 Participants | 10 Participants |
| Surgery Resection | 32 Participants | 27 Participants | 59 Participants |
| Time from initial surgery to study randomization | 375 days | 309 days | 353 days |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 31 / 35 | 23 / 35 |
| other Total, other adverse events | 33 / 34 | 24 / 25 |
| serious Total, serious adverse events | 16 / 34 | 13 / 25 |
Outcome results
Primary
Number of Participants With Progression-Free Survival at 6 Months
Progression-Free Survival (PFS) is defined as the time from randomization to progressive disease (PD) per Response Assessment in Neuro-Oncology (RANO) criteria, or death due to any cause, whichever occurs first. Participants alive without PD are censored at date of last disease evaluation. PD criteria: (A) 25% increase in sum of the products of perpendicular diameters of enhancing lesions (over best response or baseline if no decrease) on stable or increasing doses of steroids and/or one or more of the following: (B) Significant increase in T2/FLAIR non-enhancing lesion on stable or increasing doses of steroids compared to baseline scan or best response following initiation of therapy, not due to co-morbid events (C) Any new lesions (D) Clear clinical deterioration not attributable to other causes apart from the tumor, per discretion of the treating physician (E) Failure to return for evaluation due to death or deteriorating condition.
Time frame: 6 months
Population: There were 1 participant in Arm A (cediranib plus olaparib) and 10 participants in Arm B (bevacizumab) that did not receive study treatment. These participants were included in the survival analysis as part of the intention-to-treat population.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm A (Olaparib, Cediranib Maleate) | Number of Participants With Progression-Free Survival at 6 Months | 16 percentage of participants |
| Arm B (Bevacizumab) | Number of Participants With Progression-Free Survival at 6 Months | 28 percentage of participants |
Secondary
Imaging Correlates (Vascular Permeability, Tumor Perfusion and Oxygenation, Brain Tumor Cellularity)
Descriptive statistics will be provided for all continuous biomarkers outcomes. Contingency tables will be provided for categorical data. All comparisons between study arms will be adjusted for multiplicity and in particular FDR (Hochberg and Binaymini) will be used for genome data. Binary endpoints will be reported using 95% binomial confidence intervals.
Time frame: Up to 3 years
Secondary
Incidence of Adverse Events (AE)
The grade of adverse events be assessed by National Cancer Institute Common Terminology Criteria for Adverse Events 5.0. The incidence of an adverse event at a particular grade is the number of patients who experienced that adverse event/grade.
Time frame: Up to 3 years
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Anemia | No grade 3 or above events | 32 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Heart Failure | No grade 3 or above events | 33 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Lymphopenia | Grade 4 | 0 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Leukopenia | No grade 3 or above events | 33 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Transaminitis | No grade 3 or above events | 33 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Transaminitis | Grade 4 | 0 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Intracranial hemorrhage | Grade 3 | 0 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Lymphopenia | No grade 3 or above events | 32 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Intracranial hemorrhage | Grade 4 | 0 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Anemia | Grade 4 | 0 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Intracranial hemorrhage | No grade 3 or above events | 34 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Thrombocytopenia | Grade 3 | 0 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Muscle weakness of lower limb | Grade 3 | 1 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Neutropenia | Grade 3 | 1 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Muscle weakness of lower limb | Grade 4 | 0 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Thrombocytopenia | Grade 4 | 1 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Muscle weakness of lower limb | No grade 3 or above events | 33 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Leukopenia | Grade 3 | 0 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Hypokalemia | Grade 3 | 2 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Thrombocytopenia | No grade 3 or above events | 33 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Hypokalemia | Grade 4 | 0 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Neutropenia | Grade 4 | 1 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Hypokalemia | No grade 3 or above events | 32 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Hypertension | Grade 3 | 3 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Thromboembolic event | Grade 3 | 0 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Anemia | Grade 3 | 2 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Thromboembolic event | Grade 4 | 1 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Hypertension | Grade 4 | 0 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Thromboembolic event | No grade 3 or above events | 33 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Neutropenia | No grade 3 or above events | 32 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Dehydration | Grade 3 | 1 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Hypertension | No grade 3 or above events | 31 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Dehydration | Grade 4 | 0 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Leukopenia | Grade 4 | 1 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Dehydration | No grade 3 or above events | 33 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Heart Failure | Grade 3 | 0 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Paronychia | Grade 3 | 0 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Lymphopenia | Grade 3 | 2 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Paronychia | Grade 4 | 0 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Heart Failure | Grade 4 | 1 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Paronychia | No grade 3 or above events | 34 Participants |
| Arm A (Olaparib, Cediranib Maleate) | Incidence of Adverse Events (AE) | Transaminitis | Grade 3 | 1 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Paronychia | No grade 3 or above events | 24 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Transaminitis | Grade 3 | 0 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Anemia | Grade 3 | 0 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Anemia | Grade 4 | 0 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Anemia | No grade 3 or above events | 25 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Leukopenia | Grade 3 | 0 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Leukopenia | Grade 4 | 0 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Leukopenia | No grade 3 or above events | 25 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Neutropenia | Grade 3 | 0 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Neutropenia | Grade 4 | 0 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Neutropenia | No grade 3 or above events | 25 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Lymphopenia | Grade 3 | 0 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Lymphopenia | Grade 4 | 0 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Lymphopenia | No grade 3 or above events | 25 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Thrombocytopenia | Grade 3 | 1 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Thrombocytopenia | Grade 4 | 1 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Thrombocytopenia | No grade 3 or above events | 23 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Hypertension | Grade 3 | 0 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Hypertension | Grade 4 | 0 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Hypertension | No grade 3 or above events | 25 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Heart Failure | Grade 3 | 0 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Heart Failure | Grade 4 | 0 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Heart Failure | No grade 3 or above events | 25 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Transaminitis | Grade 4 | 0 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Transaminitis | No grade 3 or above events | 25 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Intracranial hemorrhage | Grade 3 | 1 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Intracranial hemorrhage | Grade 4 | 0 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Intracranial hemorrhage | No grade 3 or above events | 24 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Muscle weakness of lower limb | Grade 3 | 0 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Muscle weakness of lower limb | Grade 4 | 0 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Muscle weakness of lower limb | No grade 3 or above events | 25 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Hypokalemia | Grade 3 | 0 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Hypokalemia | Grade 4 | 0 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Hypokalemia | No grade 3 or above events | 25 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Thromboembolic event | Grade 3 | 0 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Thromboembolic event | Grade 4 | 0 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Thromboembolic event | No grade 3 or above events | 25 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Dehydration | Grade 3 | 0 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Dehydration | Grade 4 | 0 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Dehydration | No grade 3 or above events | 25 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Paronychia | Grade 3 | 1 Participants |
| Arm B (Bevacizumab) | Incidence of Adverse Events (AE) | Paronychia | Grade 4 | 0 Participants |
Secondary
Levels of Circulating Cytokines Involved With Angiogenesis
Descriptive statistics will be provided for all continuous biomarkers outcomes. Contingency tables will be provided for categorical data. All comparisons between study arms will be adjusted for multiplicity and in particular false discovery rate (FDR) (Hochberg and Binaymini) will be used for genome data. Binary endpoints will be reported using 95% binomial confidence intervals.
Time frame: Up to 3 years
Secondary
Levels of Serial Circulating Biomarkers Involved With Deoxyribonucleic Acid (DNA) Repair
Descriptive statistics will be provided for all continuous biomarkers outcomes. Contingency tables will be provided for categorical data. All comparisons between study arms will be adjusted for multiplicity and in particular FDR (Hochberg and Binaymini) will be used for genome data. Binary endpoints will be reported using 95% binomial confidence intervals.
Time frame: Up to 3 years
Secondary
Overall Survival (OS)
Overall Survival (OS) is defined as the time from randomization to death due to any cause, or censored at date last known alive.
Time frame: up to 3 years
Population: There were 1 participant in Arm A (cediranib plus olaparib) and 10 participants in Arm B (bevacizumab) that did not receive study treatment. These participants were included in the survival analysis as part of the intention-to-treat population.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A (Olaparib, Cediranib Maleate) | Overall Survival (OS) | 316 days |
| Arm B (Bevacizumab) | Overall Survival (OS) | 218 days |
Secondary
Progression Free Survival
Progression free survival is defined as the time from randomization until progressive disease or death from any cause.
Time frame: Up to 3 years
Population: There were 1 participant in Arm A (cediranib plus olaparib) and 10 participants in Arm B (bevacizumab) that did not receive study treatment. These participants were included in the survival analysis as part of the intention-to-treat population.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A (Olaparib, Cediranib Maleate) | Progression Free Survival | 118 days |
| Arm B (Bevacizumab) | Progression Free Survival | 92 days |
Secondary
Tumor Genomic Alteration
Will be assessed by whole exome sequencing. Descriptive statistics will be provided for all continuous biomarkers outcomes. Contingency tables will be provided for categorical data. All comparisons between study arms will be adjusted for multiplicity and in particular FDR (Hochberg and Binaymini) will be used for genome data. Binary endpoints will be reported using 95% binomial confidence intervals.
Time frame: Up to 3 years